Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Cancer Cell · 2023-09 · 41 (9) · 1551-1566
DOI: 10.1016/j.ccell.2023.07.011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell, 2023-09. Verfasst von Suzanne L Topalian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Bloomberg-Kimmel Institute for Cancer Immunotherapy and…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Neoplasms. Die Arbeit wurde bisher 319-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Mark Foundation For Cancer Research.
Abstract (Originalsprache)
Among new treatment approaches for patients with cancer, few have accelerated as quickly as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is administered before curative-intent surgery in treatment-naïve patients. Conventional neoadjuvant chemotherapy and radiotherapy are primarily intended to reduce tumor size, improving surgical resectability. However, recent scientific evidence outlined here suggests that neoadjuvant immunotherapy can expand and transcriptionally modify tumor-specific T cell clones to enhance both intratumoral and systemic anti-tumor immunity. It further offers a unique "window of opportunity" to explore mechanisms and identify novel biomarkers of ICB response and resistance, opening possibilities for refining long-term clinical outcome predictions and developing new, more highly effective ICB combination therapies. Here, we examine advances in clinical and scientific knowledge gleaned from studies in select cancers and describe emerging key principles relevant to neoadjuvant ICB across many cancer types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University S…
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University…
- Ankyra Therapeutics, Cambridge, MA 02142, USA.
Förderung
- NCI NIH HHS
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
- Mark Foundation For Cancer Research
- National Institutes of Health
- Swim Across America
- National Cancer Institute
- Barney Family Foundation
- Laverna Hahn Charitable Trust
Zitieren
APA
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023). Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy. Cancer Cell, 41(9), 1551-1566. https://doi.org/10.1016/j.ccell.2023.07.011
Vancouver
Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy. Cancer Cell. 2023;41(9):1551-1566. doi:10.1016/j.ccell.2023.07.011
BibTeX
@article{Topalian2023,
author = {Topalian, Suzanne L and Forde, Patrick M and Emens, Leisha A and Yarchoan, Mark and Smith, Kellie N and Pardoll, Drew M},
title = {Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy},
journal = {Cancer Cell},
year = {2023},
volume = {41},
number = {9},
pages = {1551--1566},
doi = {10.1016/j.ccell.2023.07.011}
}
EUVIMED